Importantly, PTEN loss is often accompanied by inactivating mutations of other tumor suppressor genes, such as those for retinoblastoma (Rb) or for TP53, or by the activation of oncogenes, altogether inducing stronger tumor progression, metastasis formation, and resistance to ADT [121]. The gene discussed is PTEN; the disease is neoplasm.